Dual inhibition of HIV-1 replication by integrase-LEDGF allosteric inhibitors is predominant at the post-integration stage

Retrovirology

Volumn 10, Issue 1, 2013, Pages

  Le Rouzic, Erwann ^a   Bonnard, Damien ^a   Chasset, Sophie ^a   Bruneau, Jean Michel ^a   Chevreuil, Francis ^a   Le Strat, Frédéric ^a   Nguyen, Juliette ^a   Beauvoir, Roxane ^a   Amadori, Céline ^a   Brias, Julie ^a   Vomscheid, Sophie ^a   Eiler, Sylvia ^b   Lévy, Nicolas ^b   Delelis, Olivier ^d   Deprez, Eric ^d   Saïb, Ali ^e   Zamborlini, Alessia ^e   Emiliani, Stéphane ^c   Ruff, Marc ^b   Ledoussal, Benoit ^a   Moreau, François ^a   Benarous, Richard ^a   more..

^a Biodim Mutabilis   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c INSTITUT COCHIN   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e CNRS   (France)

Author keywords

Allosteric inhibition; Antiretroviral activity; Co crystallization; Drug discovery; HIV; Integrase; Integrase inhibitor; LEDGF; Protein protein interaction inhibitor

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; EFAVIRENZ; ELVITEGRAVIR; INDINAVIR; INTEGRASE; MUT 029; MUT 047; MUT 049; MUT 062; MUT 063; MUT 075; MUT 101; NEVIRAPINE; PROTEIN P75; RALTEGRAVIR; SAQUINAVIR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ALLOSTERISM; ANTIVIRAL RESISTANCE; ARTICLE; BINDING SITE; CONCENTRATION RESPONSE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG POTENCY; DRUG STRUCTURE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; NONHUMAN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; VIRUS MUTANT; VIRUS PARTICLE;

CELL LINE; CRYSTALLOGRAPHY, X-RAY; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; PROTEIN BINDING; PROTEIN CONFORMATION; VIRUS INTEGRATION; VIRUS REPLICATION;

EID: 84889003642     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-10-144     Document Type: Article

References (73)

1. Nguyen BY, Isaacs RD, Teppler H, Leavitt RY, Sklar P, Iwamoto M, Wenning LA, Miller MD, Chen J, Kemp R, et al. Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium. Ann N Y Acad Sci 2011, 1222:83-89. 10.1111/j.1749-6632.2011.05972.x, 21434946.
2. Hare S, Gupta SS, Valkov E, Engelman A, Cherepanov P. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 2010, 464:232-236. 10.1038/nature08784, 2837123, 20118915.
3. Mouscadet JF, Delelis O, Marcelin AG, Tchertanov L. Resistance to HIV-1 integrase inhibitors: a structural perspective. Drug Resist Updat 2010, 13:139-150. 10.1016/j.drup.2010.05.001, 20570551.
4. Quashie PK, Mesplede T, Wainberg MA. Evolution of HIV integrase resistance mutations. Curr Opin Infect Dis 2013, 26:43-49.
5. Hare S, Smith SJ, Métifiot M, Jaxa-Chamiec A, Pommier Y, Hughes SH, Cherepanov P. Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol Pharmacol 2011, 80:565-572. 10.1124/mol.111.073189, 3187526, 21719464.
6. Mesplede T, Quashie PK, Osman N, Han Y, Singhroy DN, Lie Y, Petropoulos CJ, Huang W, Wainberg MA. Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure. Retrovirology 2013, 10:22. 10.1186/1742-4690-10-22, 3598531, 23432922.
7. Cherepanov P, Maertens G, Proost P, Devreese B, Van Beeumen J, Engelborghs Y, De Clercq E, Debyser Z. HIV-1 integrase forms stable tetramers and associates with LEDGF/p75 protein in human cells. J Biol Chem 2003, 278:372-381.
8. Legrain P, Rain J-C, Benarous R, Emiliani S, Berlioz-Torrent C, Blot G. Protein-protein interactions in human immunodeficiency virus. US patent 7,763,254; US Provisional 2001-333346P Nov 26 (2001); PCT/EP02/13868 Nov 26 (2002). International publication number WO 03/046176 International publication date 5 June 2003.
9. Engelman A, Cherepanov P. The lentiviral integrase binding protein LEDGF/p75 and HIV-1 replication. PLoS Pathog 2008, 4:e1000046. 10.1371/journal.ppat.1000046, 2275779, 18369482.
10. Busschots K, Vercammen J, Emiliani S, Benarous R, Engelborghs Y, Christ F, Debyser Z. The interaction of LEDGF/p75 with integrase is lentivirus-specific and promotes DNA binding. J Biol Chem 2005, 280:17841-17847.
11. Cherepanov P, Ambrosio ALB, Rahman S, Ellenberger T, Engelman A. Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75. Proc Natl Acad Sci USA 2005, 102:17308-17313. 10.1073/pnas.0506924102, 1297672, 16260736.
12. Hare S, Shun M-C, Gupta SS, Valkov E, Engelman A, Cherepanov P. A novel co-crystal structure affords the design of gain-of-function lentiviral integrase mutants in the presence of modified PSIP1/LEDGF/p75. PLoS Pathog 2009, 5:e1000259. 10.1371/journal.ppat.1000259, 2606027, 19132083.
13. Llano M, Saenz DT, Meehan A, Wongthida P, Peretz M, Walker WH, Teo W, Poeschla EM. An essential role for LEDGF/p75 in HIV integration. Science 2006, 314:461-464. 10.1126/science.1132319, 16959972.
14. Shun MC, Raghavendra NK, Vandegraaff N, Daigle JE, Hughes S, Kellam P, Cherepanov P, Engelman A. LEDGF/p75 functions downstream from preintegration complex formation to effect gene-specific HIV-1 integration. Genes Dev 2007, 21:1767-1778. 10.1101/gad.1565107, 1920171, 17639082.
15. Ciuffi A, Llano M, Poeschla E, Hoffmann C, Leipzig J, Shinn P, Ecker JR, Bushman F. A role for LEDGF/p75 in targeting HIV DNA integration. Nat Med 2005, 11:1287-1289. 10.1038/nm1329, 16311605.
16. Hare S, Di Nunzio F, Labeja A, Wang J, Engelman A, Cherepanov P. Structural basis for functional tetramerization of lentiviral integrase. PLoS Pathog 2009, 5:e1000515. 10.1371/journal.ppat.1000515, 2705190, 19609359.
17. Emiliani S, Mousnier A, Busschots K, Maroun M, Van Maele B, Tempé D, Vandekerckhove L, Moisant F, Ben-Slama L, Witvrouw M, et al. Integrase mutants defective for interaction with LEDGF/p75 are impaired in chromosome tethering and HIV-1 replication. J Biol Chem 2005, 280:25517-25523. 10.1074/jbc.M501378200, 15855167.
18. Christ F, Voet A, Marchand A, Nicolet S, Desimmie BA, Marchand D, Bardiot D, der Veken V, Nam J, Van Remoortel B, Strelkov SV, et al. Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. Nat Chem Biol 2010, 6:442-448. 10.1038/nchembio.370, 20473303.
19. Yoakim C, Deroy P, Duplessis M, Gagnon A, Goulet S, Huecke O, Lemke C, Surprenant S. Preparation of pyrazolylbenzimidazole derivatives for use as HIV replication inhibitors. Boehringer Ingelheim International GmbH, Germany 2008, WO2008/067644 A1.
20. Tsantrizos YS, Bailey MD, Bilodeau F, Carson RJ, Coulombe R, Fader L, Halmos T, Kawai S, Landry S, Laplante S, et al. Preparation of 2-(tert-butyloxy)-2-(2-methylquinolin-3-yl)acetic acid derivatives as inhibitors of human immunodeficiency virus replication 2009, Boehringer Ingelheim International GmbH, Germany, WO2009/062285 A1.
21. Yoakim C, Bailey MD, Bilodeau F, Carson RJ, Fader L, Kawai S, Laplante S, Simoneau B, Surprenant S, Thibeault C, Tsantrizos YS. Preparation of 2-alkoxy-2-(pyridin-3-yl)acetic acid derivatives as inhibitors of human immunodeficiency virus (HIV) replication. Boehringer Ingelheim International GmbH, Germany 2010, WO2010/130034 A1.
22. Fenwick C, Bethell R, Bonneau P, Duan J, Faucher A, Mason S, Poupart M, Simoneau B, Tsantrizos Y, Yoakim C. Identification of BI-C, a Novel HIV-1 non-Catalytic Site Integrase Inhibitor 2011, Boston: 18th CROI.
23. Mitchell ML, Roethle PA, Xu L, Yang H, McFadden R, Babaoglu K. Benzothiazole Compounds and Their Pharmaceutical use 2012, US: Gilead Sciences Inc, WO2012/145728 A1.
24. Bardiot D, Chaltin P, Christ F, Debyser Z, De MM, Marchand A, Marchand D, Voet A. Preparation of Thieno[2,3-b]Pyridine Derivatives as Viral Replication Inhibitors 2010, Katholieke Universiteit Leuven, Belg, WO2010/130842 A1.
25. Chaltin P, Debyser Z, De MM, Marchand A, Marchand D, Smets W, Voet A, Christ F. Pyrimidine Derivatives as Novel Viral Replication Inhibitors and Their Preparation and use in the Treatment of HIV Infection 2011, Katholieke Universiteit Leuven, Belg, WO2011/015641 A1.
26. Carlens G, Chaltin P, Christ F, Debyser Z, Marchand A, Marchand D, Voet A, De MM. Novel Antiviral Compounds 2011, Katholieke Universiteit Leuven, Belg, WO2011/076765 A1.
27. Babaoglu K, Bjornson K, Guo H, Halcomb RL, Link JO, McFadden R, Mitchell ML, Roethle P, Trenkle JD, Vivian RW, Xu L. 2-(Naphth-2-yl)Acetic Acid Derivatives as HIV Antiviral Agents and Their Preparation and use for the Treatment of AIDS 2012, USA: Gilead Sciences, Inc, WO2012/003497 A1.
28. Babaoglu K, Bjornson K, Guo H, Halcomb RL, Link JO, Liu H, Mitchell ML, Sun J, Vivian RW, Xu L. 2-(Quinolin-6-yl)Acetic Acid Derivatives as HIV Antiviral Agents and Their Preparation and use for the Treatment of AIDS 2012, USA: Gilead Sciences, Inc, WO2012/003498 A1.
29. Bell AS, Gardner IB, Gibson KR, Pryde DC, Wakenhut FM. Inhibitors of HIV Replication 2012, Pfizer Ltd., GB, WO2012/066442 A1.
30. Gerritz S, Langley DR, Li G, Meanwell NA, Pendri A, Trainor GL. Inhibitors of Human Immunodeficiency Virus Replication 2012, US: Bristol Myers Squibb Co, WO2012/033735 A1.
31. De La Rosa MA, Haidar SN, Johns BA, Velthuisen EJ. Isoquinoline Compounds and Methods for Treating HIV 2012, US: Glaxo Smithkline LLC, WO2012/102985 A1.
32. Chasset S, Chevreuil F, Ledoussal B, Le Strat F, Benarous R. Inhibitors of Viral Replication, Their Process of Preparation and Their Therapeutical Uses 2012, Laboratoire Biodim, FR, WO2012/137181 A1.
33. Chasset S, Chevreuil F, Ledoussal B, Le Strat F, Benarous R. Inhibitors of viral replication, their process of preparation and their therapeutical uses. Laboratoire Biodim FR 2012, WO2012/140243 A1.
34. Hattori K, Kurihara N, Iwaki T, Inoue T, Akiyama T, Hasegawa Y. HIV Replication Inhibitor 2013, Shionogi & Co., JP, WO2013/002357 A1.
35. Christ F, Shaw S, Demeulemeester J, Desimmie BA, Marchand A, Butler S, Smets W, Chaltin P, Westby M, Debyser Z, Pickford C. Small-molecule inhibitors of the LEDGF/p75 binding site of integrase block HIV replication and modulate integrase multimerization. Antimicrob Agents Chemother 2012, 56:4365-4374. 10.1128/AAC.00717-12, 3421592, 22664975.
36. Tsiang M, Jones GS, Niedziela-Majka A, Kan E, Lansdon EB, Huang W, Hung M, Samuel D, Novikov N, Xu Y, et al. New class of HIV-1 integrase (IN) inhibitors with a dual mode of action. J Biol Chem 2012, 287:21189-21203. 10.1074/jbc.M112.347534, 3375541, 22535962.
37. Kessl JJ, Jena N, Koh Y, Taskent-Sezgin H, Slaughter A, Feng L, de Silva S, Wu L, Le Grice SF, Engelman A, et al. Multimode, cooperative mechanism of action of allosteric HIV-1 integrase inhibitors. J Biol Chem 2012, 287:16801-16811. 10.1074/jbc.M112.354373, 3351293, 22437836.
38. Demeulemeester J, Tintori C, Botta M, Debyser Z, Christ F. Development of an AlphaScreen-based HIV-1 integrase dimerization assay for discovery of novel allosteric inhibitors. J Biomol Screen 2012, 17:618-628. 10.1177/1087057111436343, 22337657.
39. Christ F, Debyser Z. The LEDGF/p75 integrase interaction, a novel target for anti-HIV therapy. Virology 2013, 435:102-109. 10.1016/j.virol.2012.09.033, 23217620.
40. Wang H, Jurado KA, Wu X, Shun MC, Li X, Ferris AL, Smith SJ, Patel PA, Fuchs JR, Cherepanov P, et al. HRP2 determines the efficiency and specificity of HIV-1 integration in LEDGF/p75 knockout cells but does not contribute to the antiviral activity of a potent LEDGF/p75-binding site integrase inhibitor. Nucleic Acids Res 2012, 40:11518-11530. 10.1093/nar/gks913, 3526291, 23042676.
41. Feng L, Sharma A, Slaughter A, Jena N, Koh Y, Shkriabai N, Larue RC, Patel PA, Mitsuya H, Kessl JJ, et al. The A128T resistance mutation reveals aberrant protein multimerization as the primary mechanism of action of allosteric HIV-1 integrase inhibitors. J Biol Chem 2013, 288:15813-15820. 10.1074/jbc.M112.443390, 23615903.
42. Desimmie BA, Schrijvers R, Demeulemeester J, Borrenberghs D, Weydert C, Thys W, Vets S, Van Remoortel B, Hofkens J, De Rijck J, et al. LEDGINs inhibit late stage HIV-1 replication by modulating integrase multimerization in the virions. Retrovirology 2013, 10:57. 10.1186/1742-4690-10-57, 3671127, 23721378.
43. Jurado KA, Wang H, Slaughter A, Feng L, Kessl JJ, Koh Y, Wang W, Ballandras-Colas A, Patel PA, Fuchs JR, et al. Allosteric integrase inhibitor potency is determined through the inhibition of HIV-1 particle maturation. Proc Natl Acad Sci USA 2013, 110:8690-8695. 10.1073/pnas.1300703110, 3666754, 23610442.
44. Yant S, Tsai L, O'Sullivan C, Cihlar T, Balakrishnan M. Non-Catalytic Site Integrase Inhibitors Target the Integrase Domain During Virus Production and Induce a Reverse Transcription Block 2013, Gilead Sciences: Atlanta, GA, USA, Conference on Retroviruses and Opportunistic Infections.
45. Balakrishnan M, Yant SR, Tsai L, O'Sullivan C, Bam RA, Tsai A, Niedziela-Majka A, Stray KM, Sakowicz R, Cihlar T. Non-catalytic site HIV-1 integrase inhibitors disrupt core maturation and induce a reverse transcription block in target cells. PLoS One 2013, 8:e74163. 10.1371/journal.pone.0074163, 3767657, 24040198.
46. Hayouka Z, Rosenbluh J, Levin A, Loya S, Lebendiker M, Veprintsev D, Kotler M, Hizi A, Loyter A, Friedler A. Inhibiting HIV-1 integrase by shifting its oligomerization equilibrium. Proc Natl Acad Sci USA 2007, 104:8316-8321. 10.1073/pnas.0700781104, 1895947, 17488811.
47. Stanford university HIV drug resistance database. [http://hivdb.stanford.edu/index.html].
48. Fenwick C, Tremblay S, Wardrop E, Bethell R, Coulombe R, Elston R, Faucher A-M, Mason S, Simoneau B, Tsantrizos Y, Yoakim C. Resistance Studies with HIV-1 non-Catalytic Site Integrase Inhibitors 2011, Cabo, Mexico: In International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies.
49. Berg J, Doe B, Steimer KS, Wabl M. HeLa-LAV, an epithelial cell line stably infected with HIV-1. J Virol Methods 1991, 34:173-180. 10.1016/0166-0934(91)90097-J, 1687144.
50. Guiot E, Carayon K, Delelis O, Simon F, Tauc P, Zubin E, Gottikh M, Mouscadet JF, Brochon JC, Deprez E. Relationship between the oligomeric status of HIV-1 integrase on DNA and enzymatic activity. J Biol Chem 2006, 281:22707-22719. 10.1074/jbc.M602198200, 16774912.
51. Engelman A. The Pleiotropic Nature of Human Immunodeficiency Virus Type 1 Integrase Mutations. HIV-1 Integrase: Mechanism and Inhibitor Design 2011, 67-81. Wiley, Neamati N, Wang B, Drug Discovery and Development.
52. Wang JY, Ling H, Yang W, Craigie R. Structure of a two-domain fragment of HIV-1 integrase: implications for domain organization in the intact protein. EMBO J 2001, 20:7333-7343. 10.1093/emboj/20.24.7333, 125787, 11743009.
53. Berthoux L, Sebastian S, Muesing MA, Luban J. The role of lysine 186 in HIV-1 integrase multimerization. Virology 2007, 364:227-236. 10.1016/j.virol.2007.02.029, 2149894, 17397894.
54. Lesbats P, Metifiot M, Calmels C, Baranova S, Nevinsky G, Andreola ML, Parissi V. In vitro initial attachment of HIV-1 integrase to viral ends: control of the DNA specific interaction by the oligomerization state. Nucleic Acids Res 2008, 36:7043-7058. 10.1093/nar/gkn796, 2602759, 18987001.
55. Pommier Y, Marchand C. Interfacial inhibitors: targeting macromolecular complexes. Nat Rev Drug Discov 2012, 11:25-36.
56. Condra JH, Schleif WA, Blahy OM, Gabryelski LJ, Graham DJ, Quintero JC, Rhodes A, Robbins HL, Roth E, Shivaprakash M, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995, 374:569-571. 10.1038/374569a0, 7700387.
57. Gonzales MJ, Johnson E, Dupnik KM, Imamichi T, Shafer RW. Colinearity of reverse transcriptase inhibitor resistance mutations detected by population-based sequencing. J Acquir Immune Defic Syndr 2003, 34:398-402. 10.1097/00126334-200312010-00006, 2573396, 14615657.
58. Delelis O, Malet I, Na L, Tchertanov L, Calvez V, Marcelin AG, Subra F, Deprez E, Mouscadet JF. The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation. Nucleic Acids Res 2009, 37:1193-1201. 2651800, 19129221.
59. Brussel A, Sonigo P. Analysis of early human immunodeficiency virus type 1 DNA synthesis by use of a new sensitive assay for quantifying integrated provirus. J Virol 2003, 77:10119-10124. 10.1128/JVI.77.18.10119-10124.2003, 224570, 12941923.
60. Michel F, Crucifix C, Granger F, Eiler S, Mouscadet JF, Korolev S, Agapkina J, Ziganshin R, Gottikh M, Nazabal A, et al. Structural basis for HIV-1 DNA integration in the human genome, role of the LEDGF/P75 cofactor. EMBO J 2009, 28:980-991. 10.1038/emboj.2009.41, 2670869, 19229293.
61. Bushman FD, Engelman A, Palmer I, Wingfield P, Craigie R. Domains of the integrase protein of human immunodeficiency virus type 1 responsible for polynucleotidyl transfer and zinc binding. Proc Natl Acad Sci USA 1993, 90:3428-3432. 10.1073/pnas.90.8.3428, 46313, 8386373.
62. Jenkins TM, Hickman AB, Dyda F, Ghirlando R, Davies DR, Craigie R. Catalytic domain of human immunodeficiency virus type 1 integrase: identification of a soluble mutant by systematic replacement of hydrophobic residues. Proc Natl Acad Sci USA 1995, 92:6057-6061. 10.1073/pnas.92.13.6057, 41641, 7597080.
63. Yu F, Jones GS, Hung M, Wagner AH, MacArthur HL, Liu X, Leavitt S, McDermott MJ, Tsiang M. HIV-1 integrase preassembled on donor DNA is refractory to activity stimulation by LEDGF/p75. Biochemistry 2007, 46:2899-2908. 10.1021/bi602387u, 17298035.
64. Delelis O, Parissi V, Leh H, Mbemba G, Petit C, Sonigo P, Deprez E, Mouscadet JF. Efficient and specific internal cleavage of a retroviral palindromic DNA sequence by tetrameric HIV-1 integrase. PLoS One 2007, 2:e608. 10.1371/journal.pone.0000608, 1905944, 17622353.
65. Kabsch W. Xds. Acta Crystallogr D Biol Crystallogr 2010, 66:125-132. 10.1107/S0907444909047337, 2815665, 20124692.
66. Potterton E, Briggs P, Turkenburg M, Dodson E. A graphical user interface to the CCP4 program suite. Acta Crystallogr D Biol Crystallogr 2003, 59:1131-1137. 10.1107/S0907444903008126, 12832755.
67. Vagin A, Teplyakov A. Molecular replacement with MOLREP. Acta Crystallogr D Biol Crystallogr 2010, 66:22-25. 10.1107/S0907444909042589, 20057045.
68. Maignan S, Guilloteau JP, Zhou-Liu Q, Clement-Mella C, Mikol V. Crystal structures of the catalytic domain of HIV-1 integrase free and complexed with its metal cofactor: high level of similarity of the active site with other viral integrases. J Mol Biol 1998, 282:359-368. 10.1006/jmbi.1998.2002, 9735293.
69. Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. Acta Crystallogr D Biol Crystallogr 2010, 66:486-501. 10.1107/S0907444910007493, 2852313, 20383002.
70. Murshudov GN, Skubak P, Lebedev AA, Pannu NS, Steiner RA, Nicholls RA, Winn MD, Long F, Vagin AA. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr D Biol Crystallogr 2011, 67:355-367. 10.1107/S0907444911001314, 3069751, 21460454.
71. The ARP/WARP suite for automated construction and refinement of protein models. In Int. Tables for Crystallography 2001, Dordrecht, The Netherlands: Kluwer Academic, Lamzin VS, Perrakis A, Wilson KS.
72. Langer GG, Evrard GX, Carolan CG, Lamzin VS. Fragmentation-tree density representation for crystallographic modelling of bound ligands. J Mol Biol 2012, 419:211-222. 10.1016/j.jmb.2012.03.012, 3747352, 22446381.
73. DeLano WL. The PyMOL Molecular Graphics System 2002, Palo Alto, CA: Delano Scientific LLC.